The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome
Open accessAbstract
BACKGROUND: The full complement of DNA mutations that are responsible for the pathogenesis of acute myeloid leukemia (AML) is not yet known. METHODS: We used massively parallel DNA sequencing to obtain a very high level of coverage (approximately 98%) of a primary, cytogenetically normal, de novo genome for AML with minimal maturation (AML-M1) and a matched normal skin genome. RESULTS: We identified 12 acquired (somatic) mutations within the coding sequences of genes and 52 somatic point mutations in conserved or regulatory portions of the genome. All mutations appeared to be heterozygous and present in nearly all cells in the tumor sample. Four of the 64 mutations occurred in at least 1 additional AML sample in 188 samples that were tested. Mutations in NRAS and NPM1 had been identified previously in patients with AML, but two other mutations had not been identified. One of these mutations, in the IDH1 gene, was present in 15 of 187 additional AML genomes tested and was strongly associated with normal cytogenetic status; it was present in 13 of 80 cytogenetically normal samples (16%). The other was a nongenic mutation in a genomic region with regulatory potential and conservation in higher mammals; we detected it in one additional AML tumor. The AML genome that we sequenced contains approximately 750 point mutations, of which only a small fraction are likely to be relevant to pathogenesis. CONCLUSIONS: By comparing the sequences of tumor and skin genomes of a patient with AML-M1, we have identified recurring mutations that may be relevant for pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recurrent somatic point mutations in the genes coding for isocitrate dehydrogenase 1 and 2 (IDH1, IDH2) are found in a wide variety of cancers, including glioblastoma multiforme (GBM) (Yan et al., 2009) and acute myeloid leukemia (AML) (Dang et al., 2016; Mardis et al., 2009).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Mardis et al., 2009
In the citing paper
“Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML)”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“These IDH1 R132 mutations were observed in 8.5% of AML patients studied, and a significantly higher percentage of mutation was observed in the subset of patients whose tumors lacked cytogenetic abnormalities”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“In an AML case with an IDH1 mutation that was sequenced in its entirety (Mardis et al., 2009), there were a relatively small total number of somatic, non-synonymous mutations.”
From The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate (2010) · cites this paper as Mardis et al., 2009
In the citing paper
“IDH1/2 mutations have been identified in a range of tumor types, including solid tumors (e.g., gliomas and chondrosarcomas) and blood cancers like acute myelogenous leukemia (169, 170, 171).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [170]
In the citing paper
“the lack of evidence that 2HG was acting as a mutagen (Mardis et al., 2009)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“Genomic sequencing of gliomas (Parsons et al., 2008; Yan et al., 2009) and acute myelogenous leukemia (Mardis et al., 2009) identified mutations in two isoforms of NADP+-dependent isocitrate dehydrogenase (IDH1 and IDH2).”
From Cellular Metabolism and Disease: What Do Metabolic Outliers Teach Us? (2012) · cites this paper as Mardis et al., 2009
In the citing paper
“the concentrations at which it accumulates under pathogenic conditions suggests HIF-1α stabilisation and impaired collagen biogenesis may contribute to tumorigenicity126-130.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [129]
In the citing paper
“Treatment of AML with targeted therapies is particularly promising due to the fact that AMLs have far fewer mutations than most other adult cancers, with an average of only 13 mutations (Mardis et al, 2009; Cancer Genome Atlas Research Network, 2013).”
From Unlocking the potential of retinoic acid in anticancer therapy (2014) · cites this paper as Mardis et al, 2009
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Accurate whole human genome sequencing using reversible terminator chemistry
Bentley, D. R., Balasubramanian, S., Swerdlow, H. P., Smith, G. P., Milton, J., Brown, C. G., Hall, K. P., Evers, D. J., Barnes, C. L., Bignell, H. R., et al. (2008) · Nature · doi:10.1038/nature07517 · Cited by 3,684
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009) · Nature · doi:10.1038/nature07943 · Cited by 3,625
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Mapping short DNA sequencing reads and calling variants using mapping quality scores
Li, H., Ruan, J., & Durbin, R. (2008) · Genome Research · doi:10.1101/gr.078212.108 · Cited by 2,638
Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype
Falini, B., Mecucci, C., Tiacci, E., Alcalay, M., Rosati, R., Pasqualucci, L., La Starza, R., Diverio, D., Colombo, E., Santucci, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041974 · Cited by 1,892
Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
Schlenk, R. F., Döhner, K., Krauter, J., Fröhling, S., Corbacioglu, A., Bullinger, L., Habdank, M., Späth, D., Morgan, M., Benner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074306 · Cited by 1,628
Byrd, J. C. (2002) · Blood · doi:10.1182/blood-2002-03-0772 · Cited by 1,594
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
Ley, T. J., Mardis, E. R., Ding, L., Fulton, B., McLellan, M. D., Chen, K., Dooling, D. J., Dunford-Shore, B. H., McGrath, S. D., Hickenbotham, M. T., et al. (2008) · Nature · doi:10.1038/nature07485 · Cited by 1,434
Self-citationPrognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Cited by
Sorted by citations
Items 601–700 of 1,003
Mutations in the Isocitrate Dehydrogenase Genes IDH1 and IDH2 in Tumors
Schaap, F. G., French, P. J., & Bovée, J. V. M. G. (2012) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e31827b654d · Cited by 80
The large-scale distribution of somatic mutations in cancer genomes
Hodgkinson, A., Chen, Y., & Eyre‐Walker, A. (2011) · Human Mutation · doi:10.1002/humu.21616 · Cited by 80
Evolutionary constraint facilitates interpretation of genetic variation in resequenced human genomesPreprint
Goode, D. L., Cooper, G. M., Schmutz, J., Dickson, M. C., Gonzales, E., Tsai, M., Karra, K., Davydov, E. V., Batzoglou, S., Myers, R., et al. (2010) · Genome Research · doi:10.1101/gr.102210.109 · Cited by 81
The Leukemias: A Half-Century of Discovery
Freireich, E. J., Wiernik, P. H., & Steensma, D. P. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.1034 · Cited by 79
Ferrone, C. K., Blydt-Hansen, M., & Rauh, M. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020626 · Cited by 80
2-HG Inhibits Necroptosis by Stimulating DNMT1-Dependent Hypermethylation of the RIP3 Promoter
Yang, Z., Jiang, B., Wang, Y., Ni, H., Zhang, J., Xia, J., Shi, M., Hung, L.-M., Ruan, J., Mak, T. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.012 · Cited by 78
Camelo-Piragua, S. I., Jansen, M., Ganguly, A., Kim, J. C., Cosper, A. K., Dias-Santagata, D. C., Nutt, C. L., Iafrate, A. J., & Louis, D. N. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31820565f9 · Cited by 78
Nakagawa, M., Nakatani, F., Matsunaga, H., Seki, T., Endo, M., Ogawara, Y., Machida, Y., Katsumoto, T., Yamagata, K., Hattori, A., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0929-9 · Cited by 78
Isocitrate dehydrogenase mutations in leukemia
McKenney, A. S., & Levine, R. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67266 · Cited by 78
Diagnostic Applications of High-Throughput DNA Sequencing
Boyd, S. D. (2012) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164026 · Cited by 78
Translational and clinical implications of the genetic landscape of prostate cancer
Spratt, D. E., Zumsteg, Z. S., Feng, F. Y.-C., & Tomlins, S. A. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.76 · Cited by 78
Elhammali, A., Ippolito, J. E., Collins, L., Crowley, J., Marasa, J., & Piwnica-Worms, D. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0572 · Cited by 77
Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations
Sugimoto, Y., Muramatsu, H., Makishima, H., Prince, C. J., Jankowska, A. M., Yoshida, N., Xu, Y., Nishio, N., Hama, A., Yagasaki, H., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08196.x · Cited by 77
Patient-oriented gene set analysis for cancer mutation data
Boca, S. M., Kinzler, K. W., Velculescu, V. E., Vogelstein, B., & Parmigiani, G. (2010) · Genome biology · doi:10.1186/gb-2010-11-11-r112 · Cited by 77
Mian, S. A., Smith, A., Kulasekararaj, A. G., Kizilors, A., Mohamedali, A. M., Lea, N. C., Mitsopoulos, C., Ford, K., Nasser, E. E., Seidl, T., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.075325 · Cited by 77
Fathi, A. T., Sadrzadeh, H., Comander, A. H., Higgins, M. J., Bardia, A., Perry, A. M., Burke, M. E., Silver, R. M., Matulis, C. R., Straley, K. S., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0417 · Cited by 77
The three-dimensional cancer genome
Corces, M. R., & Corces, V. G. (2016) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2016.01.002 · Cited by 77
Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond
Teoh, S. T., & Lunt, S. Y. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1406 · Cited by 77
Clinical impact of molecular biomarkers in gliomas
Siegal, T. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.10.004 · Cited by 76
Acute myeloid leukemia with mutated nucleophosmin (NPM1): Any hope for a targeted therapy?
Falini, B., Gionfriddo, I., Cecchetti, F., Ballanti, S., Pettirossi, V., & Martelli, M. P. (2011) · Blood Reviews · doi:10.1016/j.blre.2011.06.001 · Cited by 76
Lethal Mutagenesis: Targeting the Mutator Phenotype in Cancer
Fox, E., & Loeb, L. A. (2010) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.10.005 · Cited by 76
Sexual dimorphism in glioma glycolysis underlies sex differences in survival
Ippolito, J. E., Yim, A. K., Luo, J. R., Chinnaiyan, P., & Rubin, J. B. (2017) · JCI Insight · doi:10.1172/jci.insight.92142 · Cited by 76
The oncometabolite 2-hydroxyglutarate inhibits microglial activation via the AMPK/mTOR/NF-κB pathway
Han, C., Zheng, J., Sun, L., Yang, H., Cao, Z., Zhang, X., Zheng, L. T., & Zhen, X.-C. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0225-9 · Cited by 75
Reactive oxygen species: Are they important for haematopoiesis?
Sardina, J. L., López-Ruano, G., Sánchez-Sánchez, B., Llanillo, M., & Hernández‐Hernández, Á. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.03.005 · Cited by 75
Metabolic Mechanisms of Epigenetic Regulation
Meier, J. L. (2013) · ACS Chemical Biology · doi:10.1021/cb400689r · Cited by 75
IDH1 and IDH2: Not Your Typical Oncogenes
Reitman, Z. J., Parsons, D. W., & Yan, H. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.02.024 · Cited by 75
Chen, J.-Y., Lai, Y.-S., Tsai, H., Kuo, C.-C., Yen, B. L., Yeh, S., Sun, H. S., & Hung, W.-C. (2016) · Scientific Reports · doi:10.1038/srep32428 · Cited by 75
The Tricarboxylic Acid Cycle at the Crossroad Between Cancer and Immunity
Scagliola, A., Mainini, F., & Cardaci, S. (2019) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.7974 · Cited by 75
Mitochondrial dependency in progression of acute myeloid leukemia
Basak, N. P., & Banerjee, S. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.01.006 · Cited by 75
TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations: Figure 1
Kim, Y.-H., Pierscianek, D., Mittelbronn, M. G. A., Vital, A., Mariani, L., Hasselblatt, M., & Ohgaki, H. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200133 · Cited by 74
Xing, D., Tan, L., Chang, C.-H., Li, H., & Xie, X. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013106118 · Cited by 74
AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches
Hatlen, M. A., Wang, L., & Nimer, S. D. (2012) · Frontiers of Medicine · doi:10.1007/s11684-012-0206-6 · Cited by 74
IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
Cerchione, C., Romano, A., Daver, N. G., Dinardo, C. D., Jabbour, E. J., Konopleva, M. Y., Ravandi‐Kashani, F., Kadia, T. M., Martelli, M. P., Isidori, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.639387 · Cited by 73
Pediatric Acute Myeloid Leukemia
Tarlock, K., & Meshinchi, S. (2014) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2014.09.007 · Cited by 73
Han, S. J., Jang, H., Noh, M. R., Kim, J., Kong, M. J., Kim, J. I., Park, J., & Park, K. M. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030349 · Cited by 73
Schweiger, M. R., Kerick, M., Timmermann, B., & Isau, M. (2011) · Cancer and Metastasis Reviews · doi:10.1007/s10555-011-9278-z · Cited by 72
Impact of Genetic Features on Treatment Decisions in AML
Döhner, H., & Gaidzik, V. I. (2011) · Hematology · doi:10.1182/asheducation-2011.1.36 · Cited by 72
Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas
Kato, Y. (2014) · Brain Tumor Pathology · doi:10.1007/s10014-014-0202-4 · Cited by 72
Dinardo, C. D., Patel, K. P., Garcia‐Manero, G., Luthra, R., Pierce, S. A., Borthakur, G. M., Jabbour, E. J., Kadia, T. M., Pemmaraju, N., Konopleva, M. Y., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.855309 · Cited by 72
Kalinina, J., Ahn, J. Y., Devi, N. S., Wang, L., Li, Y., Olson, J. J., Glantz, M., Smith, T. W., Kim, E. L., Giese, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2965 · Cited by 72
Cleven, A. H. G., Suijker, J., Agrogiannis, G., Bruijn, I. H. B., Frizzell, N., Hoekstra, A. S., Wijers‐Koster, P. M., Cleton-Jansen, A., & Bovée, J. V. M. G. (2017) · Clinical Sarcoma Research · doi:10.1186/s13569-017-0074-6 · Cited by 72
Cancer stem cells: a potential target for cancer therapy
Qiu, H. Y., Fang, X., Luo, Q., & Ouyang, G. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-1920-4 · Cited by 72
Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia
Li, M., Collins, R., Jiao, Y., Ouillette, P. D., Bixby, D. L., Erba, H. P., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Malek, S. N. (2011) · Blood · doi:10.1182/blood-2011-05-356204 · Cited by 71
Kunimoto, H., Fukuchi, Y., Sakurai, M., Sadahira, K., Ikeda, Y., Okamoto, S., & Nakajima, H. (2012) · Scientific Reports · doi:10.1038/srep00273 · Cited by 71
Altered cancer cell metabolism in gliomas with mutant IDH1 or IDH2
Borodovsky, A., Seltzer, M. J., & Riggins, G. J. (2011) · Current Opinion in Oncology · doi:10.1097/cco.0b013e32834d816a · Cited by 71
The role of targeted therapy in the management of patients with AML
Perl, A. E. (2017) · Hematology · doi:10.1182/asheducation-2017.1.54 · Cited by 71
Urban, D. J., Martinez, N. J., Davis, M. I., Brimacombe, K. R., Cheff, D. M., Lee, T. D., Henderson, M. J., Titus, S. A., Pragani, R., Rohde, J. M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12630-x · Cited by 71
Characteristics and prognostic impact ofIDHmutations in AML: a COG, SWOG, and ECOG analysis
Zarnegar‐Lumley, S., Alonzo, T. A., Gerbing, R. B., Othus, M. K. D., Sun, Z., Ries, R. E., Wang, J., Leonti, A. R., Kutny, M. A., Ostronoff, F., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008282 · Cited by 70
Self-citationChronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics
Landau, D. A., & Wu, C. J. (2013) · Genome Medicine · doi:10.1186/gm451 · Cited by 70
Clinical implications of molecular markers in acute myeloid leukemia
Käyser, S., & Levis, M. J. (2018) · European Journal Of Haematology · doi:10.1111/ejh.13172 · Cited by 70
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma
Spitzer, A., Gritsch, S., Nomura, M., Jucht, A., Fortin, J., Raviram, R., Weisman, H. R., Gonzalez Castro, L. N., Druck, N., Chanoch-Myers, R., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.03.008 · Cited by 69
Mardis, E. R. (2012) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2012.03.005 · Cited by 69
Self-citationAromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers
Miller, C. A., Gindin, Y., Lu, C., Griffith, O. L., Griffith, M., Shen, D., Hoog, J., Li, T., Larson, D. E., Watson, M. A., et al. (2016) · Nature Communications · doi:10.1038/ncomms12498 · Cited by 69
Self-citationThe role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia
Nassereddine, S., Lap, C. J. G., Haroun, F., & Tabbara, I. A. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3161-0 · Cited by 69
Next generation sequencing reveals genetic landscape of hepatocellular carcinomas
Li, S., & Mao, M. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.027 · Cited by 69
Pecci, A., Noris, P., & Balduini, C. L. (2012) · Hämostaseologie · doi:10.5482/ha12050001 · Cited by 69
Dong, W., Keibler, M. A., & Stephanopoulos, G. N. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.02.002 · Cited by 69
Fathi, A. T., Kim, H. T., Soiffer, R. J., Levis, M. J., Li, S., Kim, A. S., Mims, A. S., DeFilipp, Z. M., El-Jawahri, A. R., McAfee, S. L., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008632 · Cited by 68
Personalized therapies in the cancer "omics" era
Ocaña, A., & Pandiella, A. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-202 · Cited by 68
Gene mutations of acute myeloid leukemia in the genome era
Naoe, T., & Kiyoi, H. (2013) · International Journal of Hematology · doi:10.1007/s12185-013-1257-4 · Cited by 68
Acquired Mutations That Affect Pre-mRNA Splicing in Hematologic Malignancies and Solid Tumors
Scott, L. M., & Rebel, V. I. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt257 · Cited by 68
The role of targeted therapy in the management of patients with AML
Perl, A. E. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009829 · Cited by 68
Métellus, P., Colin, C., Taïeb, D., Guedj, É., Nanni‐Metellus, I., de Paula, A. M., Colavolpe, C., Fuentes, S., Dufour, H., Barrie, M., et al. (2011) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0625-2 · Cited by 67
Mutational profiling of kinases in glioblastoma
Bleeker, F. E., Lamba, S., Zanon, C., Molenaar, R. J., Hulsebos, T. J. M., Troost, D., van Tilborg, A. A., Vandertop, W. P., Leenstra, S., Noorden, C. J. F. V., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-718 · Cited by 67
Shiba, N., Yoshida, K., Shiraishi, Y., Okuno, Y., Yamato, G., Hara, Y., Nagata, Y., Chiba, K., Tanaka, H., Terui, K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.14247 · Cited by 67
Mutation in GNE is associated with severe congenital thrombocytopenia
Fütterer, J. W., Dalby, A., Lowe, G., Johnson, B., Simpson, M. A., Motwani, J., Williams, M., Watson, S. P., & Morgan, N. V. (2018) · Blood · doi:10.1182/blood-2018-04-847798 · Cited by 67
Pandolfi, A., Barreyro, L., & Steidl, U. G. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0109 · Cited by 66
Exploiting metabolic vulnerabilities for personalized therapy in acute myeloid leukemia
Stuani, L., Sabatier, M., & Sarry, J. (2019) · BMC Biology · doi:10.1186/s12915-019-0670-4 · Cited by 66
Handschuh, L. (2019) · Journal of Oncology · doi:10.1155/2019/7239206 · Cited by 66
Melanomas of unknown primary have a mutation profile consistent with cutaneous sun‐exposed melanoma
Dutton‐Regester, K., Kakavand, H., Aoude, L. G., Stark, M. S., Gartside, M. G., Johansson, P. A., O’Connor, L., Lanagan, C., Tembe, V., Pupo, G. M., et al. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12153 · Cited by 66
Wang, X., Dai, H., Wang, Q., Wang, Q., Xu, Y., Wang, Y., Sun, A., Ruan, J., Chen, S., & Wu, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061341 · Cited by 66
Tan, F., Jiang, Y., Sun, N., Chen, Z., Lv, Y., Shao, K., Li, N., Qiu, B., Gao, Y., Li, B., et al. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.008821 · Cited by 66
Copy number variation in the cattle genome
Liu, G. E., & Bickhart, D. M. (2012) · Functional & Integrative Genomics · doi:10.1007/s10142-012-0289-9 · Cited by 66
O’Keefe, L. V., Colella, A. D., Dayan, S., Chen, Q., Choo, A., Jacob, R. P., Price, G. R., Venter, D. J., & Richards, R. I. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq495 · Cited by 66
Enzymatic assay for quantitative analysis of (d)-2-hydroxyglutarate
Balß, J., Pusch, S., Beck, A.-C., Herold‐Mende, C. C., Krämer, A., Thiede, C., Buckel, W., Langhans, C., Okun, J. G., & von Deimling, A. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1060-y · Cited by 66
Hao, X., Gu, H., Chen, C., Huang, D., Zhao, Y., Xie, L., Zou, Y., Shu, H. S., Zhang, Y., He, X., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.11.013 · Cited by 67
RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity
Wilhelm, B. T., Briau, M., Austin, P., Faubert, A., Boucher, G., Chagnon, P., Hope, K. J., Girard, S., Mayotte, N., Landry, J., et al. (2010) · Blood · doi:10.1182/blood-2010-07-293332 · Cited by 65
Next‐generation sequencing – feasibility and practicality in haematology
Kohlmann, A., Großmann, V., Nadarajah, N., & Haferlach, T. (2013) · British Journal of Haematology · doi:10.1111/bjh.12194 · Cited by 65
The role of mitochondrial electron transport in tumorigenesis and metastasis
Tan, A. S., Baty, J. W., & Berridge, M. V. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.10.016 · Cited by 65
Self-citationPredictive and prognostic factors for gliomas
Ducray, F., Idbaïh, A., Wang, X.-W., Cheneau, C., Labussière, M., & Sanson, M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.202 · Cited by 65
Balancing biosynthesis and bioenergetics: metabolic programs in oncogenesis
Barger, J. F., & Plas, D. R. (2010) · Endocrine Related Cancer · doi:10.1677/erc-10-0106 · Cited by 65
Sun, Y., Chen, B.-R., & Deshpande, A. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00041 · Cited by 64
Mito, J. K., Bishop, J. A., Sadow, P. M., Stelow, E. B., Faquin, W. C., Mills, S. E., Krane, J. F., French, C. A., Fletcher, C. D. �., Hornick, J. L., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001064 · Cited by 64
Clonal Hematopoiesis: Somatic Mutations in Blood Cells and Atherosclerosis
Natarajan, P., Jaiswal, S., & Kathiresan, S. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.001926 · Cited by 63
Dyer, M. J. S., Akasaka, T., Capasso, M., Dusanjh, P., Lee, Y. F., Karran, E. L., Nagel, I., Vater, I., Cario, G., & Siebert, R. (2009) · Blood · doi:10.1182/blood-2009-09-235986 · Cited by 63
NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes
An, Ö., Pendino, V., D’Antonio, M., Ratti, E., Gentilini, M., & Ciccarelli, F. D. (2014) · Database · doi:10.1093/database/bau015 · Cited by 63
Chen, C., Hao, X., Lai, X., Liu, L., Zhu, J., Shao, H., Huang, D., Gu, H., Zhang, T., Yu, Z., et al. (2021) · Science Advances · doi:10.1126/sciadv.abd6280 · Cited by 63
Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
Hvinden, I. C., Cadoux-Hudson, T. A. D., Schofield, C. J., & McCullagh, J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100469 · Cited by 63
The effect of next-generation sequencing technology on complex trait research
Day-Williams, A., & Zeggini, E. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02437.x · Cited by 63
IDH Mutations in Tumorigenesis and Their Potential Role As Novel Therapeutic Targets
Krell, D., Mulholland, P. J., Frampton, A. E., Krell, J., Stebbing, J., & Bardella, C. (2013) · Future Oncology · doi:10.2217/fon.13.143 · Cited by 63
The role of mutations in epigenetic regulators in myeloid malignancies
Woods, B. A., & Levine, R. L. (2014) · Immunological Reviews · doi:10.1111/imr.12246 · Cited by 63
IDH1 Gene Mutations: A New Paradigm in Glioma Prognosis and Therapy?
Labussière, M., Sanson, M., Idbaïh, A., & Delattre, J. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0218 · Cited by 63
Pham, M. H., Zada, G., Mosich, G. M., Chen, T. C., Giannotta, S. L., Wang, K., & Mack, W. J. (2011) · Neurosurgical FOCUS · doi:10.3171/2011.2.focus1117 · Cited by 63
Metabolic synthetic lethality in cancer therapy
Zecchini, V. R., & Frezza, C. (2016) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2016.12.003 · Cited by 63
Mutant IDH in Gliomas: Role in Cancer and Treatment Options
Solomou, G., Finch, A., Asghar, A., & Bardella, C. (2023) · Cancers · doi:10.3390/cancers15112883 · Cited by 62
Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis
Eriksson, A., Lennartsson, A., & Lehmann, S. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.009 · Cited by 62
Matteo, D. A., Grunseth, A. J., Gonzalez, E. R., Anselmo, S. L., Kennedy, M. A., Moman, P., Scott, D. A., Hoang, A. D., & Sohl, C. D. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.776179 · Cited by 62
Jakob, C. G., Upadhyay, A. K., Donner, P. L., Nicholl, E., Addo, S. N., Qiu, W., Ling, C., Gopalakrishnan, S. M., Torrent, M., Cepa, S. P., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00305 · Cited by 62
Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical Indications
Liu, Y., Lang, F., Chou, F.-J., Zaghloul, K. A., & Yang, C. (2020) · Biomedicines · doi:10.3390/biomedicines8090294 · Cited by 62
Astolfi, A., Urbini, M., Indio, V., Nannini, M., Genovese, C. G., Santini, D., Saponara, M., Mandrioli, A., Ercolani, G., Brandi, G., et al. (2015) · BMC Genomics · doi:10.1186/s12864-015-1982-6 · Cited by 61
Metadata
- Authors
- Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., Fulton, L. A., Locke, D. P., Magrini, V. J., Abbott, R. M., Vickery, T. L., Reed, J. S., Robinson, J. S., Wylie, T., Smith, S. M., Carmichael, L., Eldred, J. M., Harris, C. C., Walker, J., Peck, J. B., Du, F., Dukes, A. F., Sanderson, G. E., Brummett, A. M., Clark, E., McMichael, J. F., Meyer, R. J., Schindler, J. K., Pohl, C. S., Wallis, J. W., Shi, X., Lin, L., Schmidt, H., Tang, Y., Haipek, C., Wiechert, M. E., Ivy, J. V., Kalicki, J., Elliott, G., Ries, R. E., Payton, J. E., Westervelt, P., Tomasson, M. H., Watson, M. A., Baty, J., Heath, S., Shannon, W. D., Nagarajan, R., Link, D. C., Walter, M. J., Graubert, T. A., DiPersio, J. F., Wilson, R. K., & Ley, T. J.
- Affiliations
- Washington University in St. Louis (US)
- Alvin J. Siteman Cancer Center (US)
- ORCID
- Mardis, Elaine R.
- Ding, Li
- Larson, David E.
- McLellan, Michael D.
- Chen, Ken
- Koboldt, Daniel C.
- Fulton, Robert S.
- McGrath, Sean D.
- Magrini, Vincent J.
- Vickery, Tammi L.
- Wylie, Todd
- Walker, Jason
- McMichael, Joshua F.
- Pohl, Craig S.
- Tang, Yuzhu
- Ries, Rhonda E.
- Payton, Jacqueline E.
- Tomasson, Michael H.
- Watson, Mark A.
- Heath, Sharon
- Link, Daniel C.
- Walter, Matthew J.
- Graubert, Timothy A.
- DiPersio, John F.
- Wilson, Richard K.
- Ley, Timothy J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1058-1066
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3201812
- OpenAlex
- W2134061682
- Cited by
- 2,219
- References
- 31
- Citations by year
- 2026: 35 · 2025: 44 · 2024: 57 · 2023: 76 · 2022: 81 · 2021: 107 · 2020: 104 · 2019: 115 · 2018: 120 · 2017: 126 · 2016: 136 · 2015: 154 · 2014: 163 · 2013: 197 · 2012: 251
- FWCI
- 154.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Human Genome Research Institute (U54HG003079)
- National Cancer Institute (P01CA101937)
- National Center for Research Resources (UL1RR024992)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- acute myeloid leukemia, somatic mutations, IDH1 mutation, NPM1 mutation, NRAS mutation, cytogenetically normal AML, tumor genome sequencing
- MeSH terms
- Nucleophosmin, Adult, DNA Mutational Analysis, Female, Gene Frequency, Humans, Isocitrate Dehydrogenase, Male, Middle Aged, Mutation, Leukemia, Myeloid, Acute, Genome, Human, Point Mutation, Sequence Analysis, DNA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
